To the Editor Primary results from the Comparison of Acute Treatments in Cancer Hemostasis (CATCH) trial1 were reported as negative, but the authors found an association between tinzaparin use compared with warfarin and reduction in the secondary outcome of clinically relevant nonmajor bleeding. Analysis of serious adverse events and mortality from this trial leads us to question the authors’ overall conclusions.
Maruyama A, Tejani AM, Perry TL. Tinzaparin vs Warfarin for Acute Venous Thromboembolism. JAMA. 2016;315(2):200. doi:10.1001/jama.2015.15067